Equity Profile

PTGX

Protagonist Therapeutics, Inc.

Health CareBiotechnology$6.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Protagonist Therapeutics, Inc. (PTGX) is a biotechnology company focused on developing novel therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth indicates how well the company is expanding its market presence and can signal future profitability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Protagonist Therapeutics, Inc. (PTGX) is a biotechnology company focused on developing novel therapies for serious diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as the demand for innovative treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1-2026, Protagonist reported an EPS of $0.05, significantly beating expectations of a loss. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially after the surprise EPS beat last quarter. However, the lack of revenue guidance adds a layer of uncertainty.

Bull Case

If Protagonist continues to show strong EPS performance and provides positive updates on clinical trials, it could lead to increased investor confidence and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides negative updates on its clinical trials, it could lead to a significant decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials can greatly influence investor sentiment and are crucial for understanding the company's future prospects.

Will there be any revenue guidance provided for the upcoming quarters?

Clear revenue guidance can help set expectations for growth and profitability, which are critical for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential impact of positive clinical trial results, which could lead to stronger-than-expected EPS growth.

Supporting Evidence

The options market is pricing in an 18.21% move, indicating high expectations for volatility.

The recent EPS surprise of +107.67% shows the company's potential to outperform expectations.

Insider selling activity may indicate a lack of confidence in the near-term outlook, which could contrast with the market's optimistic sentiment.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to communicate its growth potential and the success of its product pipeline.

Bull Confirmed If

A positive update on clinical trial results could confirm the bull case and drive the stock higher.

Bear Confirmed If

Failure to provide any revenue guidance or negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.21%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$184,572.50

1,750 sh

1 insider

Net

$184,572.50

Net selling

Most Active Insiders· 1 open-market trade

Chief Financial OfficerAli Asif
$184,572.50

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Protagonist beats expectations and raises guidance, history suggests a potential stock increase of around 2.89%.

In-Line / Cautious

If the results are in line but management is cautious, the stock may see muted movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential decline of around 0.80%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Any revenue guidance or projections for the upcoming quarters.
3Management's commentary on market conditions and competitive landscape.
4Insights into potential partnerships or collaborations.
5Details on operational efficiencies or cost management strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Protagonist Therapeutics, Inc. (PTGX) is a biotechnology company focused on developing novel therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth indicates how well the company is expanding its market presence and can signal future profitability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1-2026, Protagonist reported an EPS of $0.05, significantly beating expectations of a loss. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially after the surprise EPS beat last quarter. However, the lack of revenue guidance adds a layer of uncertainty.

Bull Case

If Protagonist continues to show strong EPS performance and provides positive updates on clinical trials, it could lead to increased investor confidence and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides negative updates on its clinical trials, it could lead to a significant decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials can greatly influence investor sentiment and are crucial for understanding the company's future prospects.

Will there be any revenue guidance provided for the upcoming quarters?

Clear revenue guidance can help set expectations for growth and profitability, which are critical for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential impact of positive clinical trial results, which could lead to stronger-than-expected EPS growth.

Supporting Evidence

The options market is pricing in an 18.21% move, indicating high expectations for volatility.

The recent EPS surprise of +107.67% shows the company's potential to outperform expectations.

Insider selling activity may indicate a lack of confidence in the near-term outlook, which could contrast with the market's optimistic sentiment.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to communicate its growth potential and the success of its product pipeline.

Bull Confirmed If

A positive update on clinical trial results could confirm the bull case and drive the stock higher.

Bear Confirmed If

Failure to provide any revenue guidance or negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.21%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$184,572.50

1,750 sh

1 insider

Net

$184,572.50

Net selling

Most Active Insiders· 1 open-market trade

Chief Financial OfficerAli Asif
$184,572.50

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Protagonist beats expectations and raises guidance, history suggests a potential stock increase of around 2.89%.

In-Line / Cautious

If the results are in line but management is cautious, the stock may see muted movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential decline of around 0.80%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Any revenue guidance or projections for the upcoming quarters.
3Management's commentary on market conditions and competitive landscape.
4Insights into potential partnerships or collaborations.
5Details on operational efficiencies or cost management strategies.